Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025eJHaemOpen Access

Prognostic Value of Geriatric Characteristics in Allogeneic Haematopoietic Stem Cell Transplant Recipients Aged Over 60 Years

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiu Hue LeeCAChieh Hwee AngTTTertius Tuy

Discussion

Loading...

Member takes

Overview

Observational analysis shows increased non-relapse mortality in patients over 65, highlighting the importance of geriatric assessments.

Key Points

  • Increased non-relapse mortality was associated with age over 65 and renal insufficiency.
  • Vital metrics include 2-year overall survival of 58% and progression-free survival at 55%.
  • Retrospective examination of 66 patients undergoing haematopoietic stem cell transplant revealed significant prognostic factors.
  • Results suggest geriatric assessments can refine treatment strategies for older adults with haematological malignancies.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/68c23f63b210217d647965bbhttps://doi.org/10.1002/jha2.70115
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies2025 · 1 citations
  2. 2Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.2025
  3. 3The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51–60 Years: A Retrospective Study From the Chinese Blood and Marrow Transplant Registry2025
  4. 4[Application of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia--Review].2025
  5. 5Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC2025